Chartsonlygoup's future update (it'll live):

What is ALXN's Acquisitions (Net)?

  Alexion Pharmaceuticals Inc ( ALXN ) |
2020 - 2021 (2 years)

Acquisitions (Net) is 
$1.1B (1Y - )

ALXN Stock Price & Acquisitions (Net)

Acquisitions (Net) for ALXN competitors.
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Acquisitions (Net)

chevron_right 2021 0.0 -1.0x
( -100.0% / year avg)
chevron_left 2020 $2.1B
vertical_align_top Peak $2.1B -
vertical_align_bottom Bottom 0.0
arrow_drop_up # Up Years 0 0 of 2
years up.
arrow_drop_down # Down Years 1
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 2020 , or -45.0x faster than it's acquisitions (net) over the same period.
  • If ALXN shrinks it's stock at the same rate as it's acquisitions (net) (-100.0%/year) , it's stock price will shrink 0% and hit $0.0 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 0 years (0%) it's acquisitions (net) were also up.
  • ALXN Historical Acquisitions (Net) Table
    in $ million
    Year Acquisitions (Net) YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 $0 -100.0% $108.72 0.0%
    4/1/2020 $2,111 - $108.72 -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • An acquisition is when one company purchases most or all of another company's shares to gain control of that company. Purchasing more than 50% of a target firm's stock and other assets allows the acquirer to make decisions about the newly acquired assets without the approval of the company’s other shareholders. Acquisitions, which are very common in business, may occur with the target company's approval, or in spite of its disapproval. With approval, there is often a no-shop clause during the process.

    For more detailed definitions, please see Investopedia.